Gene therapy targeting to tumor endothelium

Bazan‐Peregrino, Miriam; Seymour, Leonard W.; Harris, Adrian L.

doi:10.1038/sj.cgt.7701001

Cited by 32 publications

(15 citation statements)

References 94 publications

(87 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both natural (vWF, FLT-1 and ICAM-2) and synthetic promoters have been used to drive endothelium-specific expression by viral and nonviral vectors. 91 The combination of highly specific promoters with highly efficient vectors (adenoviral, AAV and lentiviral) 92,93 will certainly improve initial outcomes in clinical trials of cardiovascular diseases.…”

Section: Endotheliummentioning

confidence: 99%

Physiological and tissue-specific vectors for treatment of inherited diseases

Toscano

Romero

Muñoz³

et al. 2010

Gene Ther

View full text Add to dashboard Cite

After more than 1500 gene therapy clinical trials in the past two decades, the overall conclusion is that for gene therapy (GT) to be successful, the vector systems must still be improved in terms of delivery, expression and safety. The recent development of more efficient and stable vector systems has created great expectations for the future of GT. Impressive results were obtained in three primary immunodeficiencies and other inherited diseases such as congenital blindness, adrenoleukodystrophy or junctional epidermolysis bullosa. However, the development of leukemia in five children included in the GT clinical trials for X-linked severe combined immunodeficiency and the silencing of the therapeutic gene in the chronic granulomatous disease clearly showed the importance of improving safety and efficiency. In this review, we focus on the main strategies available to achieve physiological or tissue-specific expression of therapeutic transgenes and discuss the importance of controlling transgene expression to improve safety. We propose that tissue-specific and/or physiological viral vectors offer the best balance between efficiency and safety and will be the tools of choice for future clinical trials in GT of inherited diseases.

show abstract

Section: Endotheliummentioning

confidence: 99%

Physiological and tissue-specific vectors for treatment of inherited diseases

Toscano

Romero

Muñoz³

et al. 2010

Gene Ther

View full text Add to dashboard Cite

show abstract

“…Importantly, promising effects have been observed after local administration of immune-enhancing agents into mesothelioma tumors via direct injection or via intrapleural gene therapy in clinical trials [14,15]. Encouragingly, technological advances such as CT-guided injections, gene therapy, monoclonal antibodies, and nanotechnology will further enable tumor targeting [16,17].…”

Section: Introductionmentioning

confidence: 97%

Intratumoral interleukin-2/agonist CD40 antibody drives CD4+-independent resolution of treated-tumors and CD4+-dependent systemic and memory responses

Jackaman

Nelson

2011

Cancer Immunol Immunother

View full text Add to dashboard Cite

Targeting interleukin-2 (IL-2) and/or agonist anti-CD40 antibody (Ab) into tumors represents an effective vaccination strategy that avoids systemic toxicity and resolves treated-site tumors. Here, we examined IL-2 and/or anti-CD40 Ab-driven local versus systemic T cell function and the installation of T cell memory. Single tumor studies showed that IL-2 induced a potent CD4+ and CD8+ T cell response that was limited to the draining lymph node and treated-site tumor, and lymph node tumor-specific CD8+ T cells did not upregulate CD44. A two-tumor model showed that while IL-2-treated-site tumors resolved, distal tumors continued to grow, implying limited systemic immunity. In contrast, anti-CD40 Ab treatment with or without IL-2 expanded the systemic T cell response to non-draining lymph nodes, and distal tumors resolved. Tumor-specific T cells in lymph nodes of anti-CD40 Ab ± IL-2-treated mice upregulated CD44, demonstrating activation and transition to effector/memory migratory cells. While CD40-activated CD4+ T cells were not required for eradicating treated-site tumors, they, plus CD8+ T cells, were crucial for removing distal tumors. Rechallenge/depletion experiments showed that the effector/memory phase required the presence of previously CD40/IL-2-activated CD4+ and CD8+ T cells to prevent recurrence. These novel findings show that different T cell effector mechanisms can operate for the eradication of local treated-site tumors versus untreated distal tumors and that signaling through CD40 generates a whole of body, effector/memory CD4+ and CD8+ T cell response that is amplified and prolonged via IL-2. Thus, successful immunotherapy needs to generate collaborating CD4+ and CD8+ T cells for a complete long-term protective cure.

show abstract

“…[1][2][3][4] In particular, RNAi (RNA interference)-based gene therapy, belonging to a post-transcriptional gene silencing process, is a gene-targeting technology with great potential.…”

Section: Introductionmentioning

confidence: 99%